5 results match your criteria: "Complejo Hospitalario San Luis[Affiliation]"
A Case Report of Camptocormia Coinciding With Olanzapine Use.
J Clin Psychopharmacol
April 2016
Complejo Hospitalario San Luis Palencia, Spain Hospitalario San Luis Palencia, SpainComplejo Hospitalario de Palencia. Sacyl Palencia, SpainClinical Psychologist Specialist Hospital Benito Menni Valladolid, Spain.
Objective: To longitudinally analyze the course of cognitive dimensions in schizophrenic women over a period of 31 years.
Method: Accidental sampling. Developmental longitudinal design.
A retrospective study of nursing diagnoses, outcomes, and interventions for patients with mental disorders.
Appl Nurs Res
May 2015
Complejo Hospitalario San Luis, Palencia, Spain. Electronic address:
Article Synopsis
- The study focuses on identifying common nursing diagnoses, outcomes, and interventions related to psychiatric conditions using NANDA-I, NOC, and NIC frameworks.
- Previous research has largely examined these frameworks in medical contexts, highlighting a gap in psychiatric applications.
- Data from 690 patients in psychiatric units and day-care centers in Spain revealed frequent nursing diagnoses for various mental health disorders, confirming the value of these labels in understanding patient needs.
Objective: "Medicina Paliativa" is the official journal of the Spanish Society of Palliative Care ("Sociedad Española de Cuidados Paliativos"; SECPAL) and it reflects the interests, also on bioethics, of the professionals caring terminal people. We want to know what the bioethical questions they discuss and their approaches are.
Methods: From all the published articles in "Medicina Paliativa" from 1994 to 2013 we selected those referred to bioethics topics.
[Adverse effects of antipsychotics and quality of life].
Actas Esp Psiquiatr
May 2005
Servicio de Psiquiatría, Complejo Hospitalario San Luis, Palencia.
Introduction: New antipsychotics are associated with fewer adverse effects than classical ones. However, an increase in the patient's quality of life is not clear, given the complex relationship between quality of life and schizophrenia.
Objective: To show there are no real differences in adverse effects and quality of life of schizophrenic patients treated with atypical and typical neuroleptics.